Vident Investment Advisory’s BioTelemetry, Inc. BEAT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-296,179
| Closed | -$21.3M | – | 1052 |
|
|
2020
Q4 | $21.3M | Sell |
296,179
-61,022
| -17% | -$3.19M | 0.87% | 23 |
|
|
2020
Q3 | $16.3M | Buy |
357,201
+98,198
| +38% | +$4.1M | 0.81% | 22 |
|
|
2020
Q2 | $11.7M | Buy |
259,003
+10,152
| +4% | +$455K | 0.61% | 43 |
|
|
2020
Q1 | $9.58M | Sell |
248,851
-5,687
| -2% | -$262K | 0.63% | 37 |
|
|
2019
Q4 | $11.8M | Sell |
254,538
-47,107
| -16% | -$2.04M | 0.73% | 40 |
|
|
2019
Q3 | $12.3M | Buy |
301,645
+39,749
| +15% | +$1.72M | 1.07% | 22 |
|
|
2019
Q2 | $12.6M | Buy |
261,896
+83,299
| +47% | +$4.38M | 1.01% | 40 |
|
|
2019
Q1 | $11.2M | Sell |
178,597
-12,571
| -7% | -$863K | 0.6% | 41 |
|
|
2018
Q4 | $11.4M | Buy |
+191,168
| New | +$11.5M | 0.64% | 40 |
|
|
2018
Q2 | – | Sell |
-18,094
| Closed | -$623K | – | 1007 |
|
|
2018
Q1 | $623K | Sell |
18,094
-2,377
| -12% | -$78.2K | 0.03% | 516 |
|
|
2017
Q4 | $612K | Buy |
+20,471
| New | +$593K | 0.03% | 498 |
|
|
2017
Q3 | – | Sell |
-11,239
| Closed | -$376K | – | 799 |
|
|
2017
Q2 | $376K | Buy |
+11,239
| New | +$335K | 0.03% | 360 |
|
|
2017
Q1 | – | Sell |
-19,824
| Closed | -$443K | – | 514 |
|
|
2016
Q4 | $443K | Sell |
19,824
-4,903
| -20% | -$95.9K | 0.05% | 333 |
|
|
2016
Q3 | $459K | Buy |
+24,727
| New | +$466K | 0.06% | 375 |
|
Other funds holding BEAT
Vident Investment Advisory's BEAT Position: Q1 2021 in Review
Vident Investment Advisory sold out of BioTelemetry, Inc. (BEAT) in Q1 2021, closing a stake of 296,179 shares — an estimated $21.3M sold.
Vident Investment Advisory first reported a position in BEAT in Q3 2016 and held it in 14 quarters. The position peaked at $21.3M in Q4 2020. 1 fund tracked by Wall St. Rank holds BEAT as of Q1 2021.
- Vident Investment Advisory reported no remaining BioTelemetry, Inc. position as of Q1 2021 after selling out during the quarter.
- Vident Investment Advisory sold 296,179 BioTelemetry, Inc. shares in Q1 2021, an estimated $21.3M.
- Vident Investment Advisory first reported a position in BioTelemetry, Inc. in Q3 2016 and held it in 14 quarters.
- Vident Investment Advisory's BioTelemetry, Inc. position peaked at $21.3M in Q4 2020.
- 1 fund tracked by Wall St. Rank held BioTelemetry, Inc. as of Q1 2021.
Based on Vident Investment Advisory's 13F filing for Q1 2021, filed 14 May 2021.